Swiss Basilea says profits still 2-3 years away
0
ZURICH (Reuters) - Swiss drugmaker Basilea expects to move into profit by 2018, counting on new anti-infection drugs to help mitigate setbacks such as last month's collapse of efforts to win U.S. approval for an eczema treatment.